Suitability of CD133 as a Marker for Cancer Stem Cells in Melanoma

Korn, Philippe; Kampmann, Andreas; Spalthoff, Simon; Jehn, Philipp; Tavassol, Frank; Lentge, Fritjof; Gellrich, Nils‐Claudius; Zimmerer, Rüdiger

doi:10.31557/apjcp.2021.22.5.1591

Cited by 9 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeting MSCs therapy for malignant melanoma has been making encouraging progress. 33 Therefore, cytotoxicity assay and flow cytometry were used to detect whether MSC vaccine targets MSCs. When the mouse spleen lymphocytes acted as effector cells, B16F10 cells were used as target cells.…”

Section: Resultsmentioning

confidence: 99%

Melanoma stem cell vaccine induces effective tumor immunity against melanoma

Yin

Zhao

Chang

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Melanoma stem cells (MSCs)-based vaccine strategies have been a potent immunotherapeutic approach for melanoma treatment, which aimed at inducing specific anti-tumor immunity and targeting cancer stem-like cells. As the main cancer-fighting immune cells, CD8 + T cells play an important role in vaccine-induced antitumor immunity. Here, we developed a novel MSC vaccine that induces CD8 + T cells to target melanoma stem cells specifically. The MSC vaccine was prepared for our study in order to determine the effectiveness of antitumor immunity. The proportion and activity of CD8 + T cells were examined in the spleen after immunization, in particular, the expression and cytotoxicity of the immune checkpoint of spleen lymphocytes were detected by flow cytometry and ELISA, moreover, tumor size and the number of lung metastasis nodules were observed and the specific killing effect of the vaccine was evaluated in immunized mice. We found that the MSC vaccine could promote DCs maturation, activate CD8 + T cells, suppress the expression of CTLA-4, PD-1, and Tim-3, and increase the expression of IFN-γ and GzmB of CD8 + T cells. Melanoma growth and metastasis were inhibited by the vaccine’s specific targeted killing effect. The vaccines based on melanoma stem cells (MSCs) delay the progression of melanoma by inducing anti-tumor immune responses in CD8 + T cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Melanoma stem cell vaccine induces effective tumor immunity against melanoma

Yin

Zhao

Chang

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The suspension was incubated in dark for 30 min, and the cells were washed twice with PBS. Finally, the cells were resuspended in PBS, and the percentage of CD133 + cells was measured using a BD FACSCalibur Flow Cytometer (BD Biosciences, San Diego, CA, USA) [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

The NOP14 nucleolar protein suppresses the function and stemness of melanoma stem-like cells through Wnt/beta-catenin signaling inactivation

Fang

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are closely related to tumor occurrence, development, metastasis, drug resistance, and recurrence. The role of CSCs in melanoma is poorly understood. Our previous studies suggested that the NOP14 nucleolar protein (NOP14) is involved in melanoma pathogenesis regulation. Importantly, NOP14 overexpression inhibits the Wnt/beta (β)-catenin signaling pathway, an important mechanism regulating CSCs stemness. Therefore, in this study, we aimed to explore the role of NOP14 in the stemness and function of CSCs in melanoma in vitro . CD133, a stem cell marker, was used to identify melanoma stem-like cells (SLCs). NOP14 overexpression subsequently decreased the proportion of CD133 + SLCs, impaired the colony-forming capabilities, and downregulated the expression of Nanog, SOX2, and OCT4 stem cell markers in A375 and A875 cells, suggesting that NOP14 suppresses the stemness of melanoma SLCs. NOP14 overexpression suppressed the migration, invasion, and angiogenesis-inducing ability of A375-SLCs and A875-SLCs. NOP14 overexpression also inactivated Wnt/β-catenin signaling in melanoma CD133 + SLCs. The Wnt signaling activator BML-284 alleviated the effect of NOP14 overexpression on the stemness and function of melanoma CSCs. In conclusion, NOP14 suppresses the stemness and function of melanoma SLCs by inactivating Wnt/β-catenin signaling. Thus, NOP14 is a novel target for CSC treatment in melanoma. Abbreviations : CSCs, cancer stem cells; SLCs, stem-like cells; NOP14, NOP14 nucleolar protein; SCID, severe combined immunodeficiency; β-catenin, beta-catenin; lv-NOP14, lentivirals expressing NOP14; PBS, phosphate buffer saline; HUVECs, human umbilical vein endothelial cells.

show abstract

“…In addition, it might also have a role in apoptosis inhibition, and the upregulation of FLICE-like inhibitory protein (FLIP), leading to chemoresistance [ 88 ]. This cell-surface protein is known as an important driver of tumor progression and as a CSC marker [ 89 ].…”

Section: Radiation Resistance Of Chondrosarcoma: Microenvironment Mol...mentioning

confidence: 99%

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Gilbert

Tudor

Montanari

et al. 2023

Cancers

View full text Add to dashboard Cite

Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.

show abstract

Suitability of CD133 as a Marker for Cancer Stem Cells in Melanoma

Cited by 9 publications

References 27 publications

Melanoma stem cell vaccine induces effective tumor immunity against melanoma

Melanoma stem cell vaccine induces effective tumor immunity against melanoma

The NOP14 nucleolar protein suppresses the function and stemness of melanoma stem-like cells through Wnt/beta-catenin signaling inactivation

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Contact Info

Product

Resources

About